Rong (Fiona) Huang
Lawyers
Filters
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Intuit $4 billion notes offering
The investment-grade offering comprises four tranches of notes
Vishay Intertechnology $750 million convertible senior notes offering
The 2.25% convertible notes are due 2030
AN2 Therapeutics $70 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $300 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Upgrade $100 million acquisition of Uplift
We advised Upgrade on the transaction
IDEAYA Biosciences $201 million equity offering
The common stock is listed on the Nasdaq Global Select Market
AN2 Therapeutics $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Mirion Technologies $85.6 million secondary offering
The offering consists of 9,786,153 shares of Class A common stock
Mirion Technologies $150 million registered direct offering
We advised Mirion on the offering